Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering
Synergy CHC Corp (NASDAQ:SNYR) has announced the pricing of an underwritten public offering of 1.75 million shares of common stock at $2.50 per share, aiming to raise $4.375 million in gross proceeds.
The offering includes a 45-day option for underwriters to purchase up to 262,500 additional shares. The Company will also issue underwriter warrants for up to 52,500 shares (or 60,375 if over-allotment is exercised), exercisable after 180 days. The warrants will expire in tranches over 3-5 years. The offering is expected to close on August 27, 2025, with proceeds intended for working capital and general corporate purposes.
Synergy CHC Corp (NASDAQ:SNYR) ha comunicato il prezzo di un'offerta pubblica garantita di 1,75 milioni di azioni ordinarie a $2,50 per azione, con l'obiettivo di raccogliere $4,375 milioni di proventi lordi.
L'offerta comprende un'opzione di 45 giorni per gli underwriter di acquistare fino a 262.500 azioni aggiuntive. La Societ脿 emetter脿 inoltre warrant a beneficio degli underwriter per un massimo di 52.500 azioni (o 60.375 se viene esercitata la sovrallocazione), esercitabili dopo 180 giorni. I warrant scadranno in tranche nell'arco di 3-5 anni. La chiusura dell'operazione 猫 prevista per il 27 agosto 2025, e i proventi saranno destinati al capitale circolante e ad esigenze aziendali generali.
Synergy CHC Corp (NASDAQ:SNYR) ha anunciado la fijaci贸n del precio de una colocaci贸n p煤blica suscrita de 1,75 millones de acciones ordinarias a $2,50 por acci贸n, con la intenci贸n de recaudar $4,375 millones en ingresos brutos.
La oferta incluye una opci贸n de 45 d铆as para que los colocadores compren hasta 262.500 acciones adicionales. La Compa帽铆a tambi茅n emitir谩 warrants a favor de los colocadores por hasta 52.500 acciones (o 60.375 si se ejerce la sobreasignaci贸n), ejecutables despu茅s de 180 d铆as. Los warrants vencer谩n en tramos en un periodo de 3 a 5 a帽os. Se espera que la operaci贸n cierre el 27 de agosto de 2025, y los ingresos se destinar谩n a capital de trabajo y fines corporativos generales.
Synergy CHC Corp (NASDAQ:SNYR)電� 氤错喌欤� 175毵� 欤�鞚� 瓿惦 頉勳洂 鞚胳垬(鞏鸽崝霛检澊韯半摐) 氚滍枆臧�毳� 欤茧嫻 $2.50搿� 毂呾爼頄堧嫟瓿� 氚滍憸頄堨溂氅�, 齑� $4.375氚彪鞚� 齑濎垬鞚奠潉 臁半嫭頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞚� 瓿惦鞐愲姅 鞚胳垬雼澊 於旉皜搿� 斓滊寑 262,500欤�毳� 毵れ垬頃� 靾� 鞛堧姅 45鞚� 鞓奠厴鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 須岇偓電� 鞚胳垬雼棎瓴� 斓滊寑 52,500欤� 靸侂嫻鞚� 鞗岆煱韸鸽ゼ 氚滍枆頃� 鞓堨爼鞚措┌(鞓る矂鞏茧韸鸽韸戈皜 頄夓偓霅橂┐ 60,375欤�), 鞗岆煱韸鸽姅 180鞚� 頉勳棎 頄夓偓 臧�電ロ晿瓿� 3~5雲� 霃欖晥 攵勴暊 毵岆霅╇媹雼�. 瓯半灅 毵堦皭鞚� 2025雲� 8鞗� 27鞚�搿� 鞓堨儊霅橂┌, 靾橃澋旮堨潃 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�.
Synergy CHC Corp (NASDAQ:SNYR) a annonc茅 la fixation du prix d'une offre publique souscrite de 1,75 million d'actions ordinaires 脿 2,50 $ par action, visant 脿 lever 4,375 millions $ de produit brut.
L'offre comprend une option de 45 jours permettant aux souscripteurs d'acheter jusqu'脿 262 500 actions suppl茅mentaires. La Soci茅t茅 茅mettra 茅galement des bons de souscription (warrants) pour les souscripteurs portant sur jusqu'脿 52 500 actions (ou 60 375 si l'extension est exerc茅e), exer莽ables apr猫s 180 jours. Les warrants arriveront 脿 茅ch茅ance par tranches sur 3 脿 5 ans. La cl么ture est pr茅vue pour le 27 ao没t 2025, les produits 茅tant destin茅s au fonds de roulement et 脿 des usages g茅n茅raux de la soci茅t茅.
Synergy CHC Corp (NASDAQ:SNYR) hat die Preisfestsetzung eines unterzeichneten 枚ffentlichen Angebots von 1,75 Millionen Stammaktien zu $2,50 je Aktie bekannt gegeben, mit dem Ziel, $4,375 Millionen Bruttoerl枚s zu erzielen.
Das Angebot umfasst eine 45-t盲gige Option f眉r die Underwriter zum Erwerb von bis zu 262.500 zus盲tzlichen Aktien. Das Unternehmen wird zudem Underwriter-Warrants f眉r bis zu 52.500 Aktien ausgeben (bzw. 60.375, falls die 脺berzuteilung ausge眉bt wird), die nach 180 Tagen aus眉bbar sind. Die Warrants laufen gestaffelt 眉ber 3鈥�5 Jahre ab. Der Abschluss der Transaktion wird f眉r den 27. August 2025 erwartet; die Erl枚se sollen dem Betriebskapital und allgemeinen Unternehmenszwecken dienen.
- Potential strengthening of working capital position with $4.375 million gross proceeds
- Strategic timing with SEC registration already effective
- Structured warrant expiration schedule spreading over 3-5 years reduces immediate dilution risk
- Significant dilution for existing shareholders with 1.75 million new shares
- Additional potential dilution from 262,500 share over-allotment option
- Further dilution risk from underwriter warrants of up to 52,500 shares
Insights
Synergy CHC Corp raises $4.375M through dilutive public offering at $2.50/share, primarily for working capital purposes.
Synergy's
The stated use of proceeds for "working capital and general corporate purposes" lacks specificity, suggesting the company may be strengthening its balance sheet rather than funding specific growth initiatives. This language typically indicates a need to shore up operational financing rather than strategic investments.
The underwriter warrant structure is notable, with staggered expiration dates spanning years 3-5 post-closing. This tiered approach dilutes the impact of potential future dilution while providing additional compensation to Bancroft Capital as the sole book-runner. The warrants represent approximately
For a Nasdaq-listed company like Synergy CHC, this capital raise should help maintain compliance with listing requirements while providing operational runway. However, the lack of detail regarding specific growth initiatives or strategic plans in the use of proceeds statement raises questions about the company's immediate business trajectory and financial health.
WESTBROOK, Maine, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (Nasdaq: SNYR) (鈥淪ynergy鈥� or the 鈥淐ompany鈥�), a leading consumer health and wellness company, today announced the pricing of an underwritten public offering of 1,750,000 shares of common stock at a public offering price of
The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
The Company has agreed to issue to the underwriter warrants to purchase up to 52,500 shares of common stock (or 60,375 if the over-allotment is exercised), exercisable beginning 180 days from the closing of the offering. The warrants will expire in tranches: twenty-five percent (
Bancroft Capital, LLC is acting as the sole book-running manager for the offering.
A registration statement on Form S-1 (File No. 333-289645) relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 15, 2025, and was declared effective on August 25, 2025. A final prospectus relating to the offering will be filed with the SEC and will be available at the SEC鈥檚 website at www.sec.gov or from Bancroft Capital, LLC by email at [email protected], by standard mail to 501 Office Center Drive, Suite 130, Fort Washington, PA 19034, or by telephone at +1 (484) 546-8000.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Synergy CHC Corp.
Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor庐聽and Flat Tummy庐. FOCUSfactor庐, a clinically studied brain health supplement and functional beverage line with a聽25-year legacy, enjoys established distribution in the聽U.S., Canada, and the U.K. through major retailers including聽Costco, Walmart, Amazon, BJ鈥檚, and Walgreens,聽among others. The brand continues to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy, convenience, and wholesale channels poised to drive meaningful gains in late 2025.聽Flat Tummy庐聽complements Synergy鈥檚 portfolio as a lifestyle brand focused on women鈥檚 wellness and weight management.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements that reflect management鈥檚 current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as 鈥渂elieve,鈥� 鈥渆xpects,鈥� 鈥渕ay,鈥� 鈥渓ooks to,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥減lan,鈥� 鈥渋ntend,鈥� 鈥渙n condition,鈥� 鈥渢arget,鈥� 鈥渟ee,鈥� 鈥減otential,鈥� 鈥渆stimates,鈥� 鈥減reliminary,鈥� or 鈥渁nticipates鈥� or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, the expectation that the proposed offering will be successfully completed. Further information relating to factors that may impact the Company鈥檚 results and forward-looking statements are disclosed in the Company鈥檚 filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Relations
Gateway Group
Cody Slach, Greg Robles
949.574.3860
[email protected]
FAQ
What is the size and price of SNYR's public offering in August 2025?
How will SNYR use the proceeds from its August 2025 public offering?
What is the over-allotment option in SNYR's August 2025 offering?
When will SNYR's August 2025 public offering close?
What are the terms of the underwriter warrants in SNYR's offering?
